| 股） | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 研发投入占营业收 | | | | | | | | | | 入的比例（%） | | | | | | 单位: | 股 | | | 截至报告期末股东总数 | | | | | | | | | | （户） | | | | | | 8,278 | | | | 截至报告期末表决权恢复的优先股股东总数 | | | | | | | | | | （户） | | | | | 0 | | | | | 截至报告期末持有特别表决权股份的股东总数 | | | | | | | | | | （户） | | | | | 0 | | | | | 10 | 前 | 名股东持股情况 | | | | | | | | | | | | 持有有 | | 包含转融 | | 质押、 | | 标 | | | | | | | | | | | | 持股 | | | | | | | | | | | 持股 | 限售条 | | 通借出股 | | 记或 | | 冻结 股东名称 | 股东性质 | 比例 | | | | ...

Meeting Details - The fourth meeting of the supervisory board of Jia Bi You Biotechnology (Wuhan) Co., Ltd. was held on August 18, 2025, via communication methods, with all supervisors notified on August 8, 2025 [1][2] - The meeting complied with relevant laws, regulations, and the company's articles of association regarding attendance and voting procedures [1] Resolutions Passed - The supervisory board approved the proposal regarding the 2025 semi-annual report and its summary, affirming that the report accurately reflects the company's financial status and operational results without any false statements or omissions [1][2] - The board also approved the proposal concerning the special report on the storage and usage of raised funds for the first half of 2025, confirming compliance with relevant regulations and ensuring no harm to shareholders' interests, particularly minority shareholders [2]

Fundraising Overview - The company raised a total of RMB 717 million from the issuance of 30 million shares at RMB 23.90 per share, with a net amount of RMB 648.33 million after deducting issuance costs [1] - As of June 30, 2025, the company had a remaining balance of RMB 7.30 million in its fundraising account [3] Fund Management - The company has established a management system for fundraising in accordance with regulatory guidelines to ensure proper use and protection of investor rights [1] - A tripartite supervision agreement was signed with the underwriter and banks to ensure the funds are used specifically for their intended purposes [2][3] Fund Utilization - The company completed the investment projects related to the expansion of microbial oil and polyunsaturated fatty acid microencapsulation production lines in 2023, with final payments made during the reporting period [4][5] - The research center construction project has fully utilized the committed fundraising amount, with excess funding derived from interest income [4][8] Financial Management - The company has not used any excess fundraising to permanently supplement working capital or repay bank loans during the reporting period [5][6] - The board approved the temporary use of up to RMB 12 million of idle funds for cash management, ensuring it does not affect ongoing projects [5] Compliance and Reporting - The company has adhered to all relevant laws and regulations regarding the use of fundraising and has disclosed the usage status in a timely manner [7]

Core Viewpoint - The company has implemented a "Quality Improvement, Efficiency Enhancement, and Return to Investors" action plan, achieving significant growth in net profit and expanding its product offerings in various sectors, including infant nutrition, animal nutrition, and beauty care [1][2][5]. Group 1: Business Development - The company achieved a net profit of 108 million yuan, a year-on-year increase of 59.01% [1]. - In the infant nutrition sector, the demand for ARA and algal oil DHA products has steadily increased, with significant contributions from core customer sales growth [1]. - The company has successfully advanced collaborations with major international clients such as Danone, Nestlé, and Abbott, focusing on algal oil DHA products and HMOs [1][2]. Group 2: Product Innovation - The company has developed EncapDHA algal oil emulsion, which can be used in various functional food applications [2]. - In the animal nutrition sector, the company launched 27 new fatty acid products, enhancing its B2C business through integrated operations [2]. - The company is actively developing high-value products such as 2'-FL, 3-FL, and EPA, with successful pilot tests and regulatory submissions [4]. Group 3: Research and Development - The company invested 19.76 million yuan in R&D in the first half of 2025, employing 97 R&D personnel and holding 191 authorized patents [2][3]. - The company is advancing its AI and synthetic biology strategy, enhancing its intelligent R&D platform and bioinformatics capabilities [3]. Group 4: Operational Efficiency - The company has implemented a digital transformation strategy, improving supply chain data analysis and decision-making capabilities [5]. - The company achieved record production levels through capacity optimization and digital management [5]. Group 5: Corporate Governance - The company has maintained effective governance practices, holding multiple board meetings and enhancing its ESG governance framework [6][7]. - The company is focused on improving the capabilities of its key personnel through training and development initiatives [7]. Group 6: Investor Relations - The company emphasizes shareholder returns through cash dividend distributions and potential share buybacks, with plans to repurchase shares within a specified range [8][9]. - The company is actively engaging with investors through various communication channels and events to ensure transparency and information dissemination [10].

证券日报网讯 8月18日晚间，嘉必优发布公告称，2025年半年度公司实现营业收入306，732，098.82 元，同比增长17.60%；归属于上市公司股东的净利润为107，950，937.97元，同比增长59.01%。 （文章来源：证券日报） ...

Core Viewpoint - The article highlights the strong growth performance of Jiabiyou in the first half of 2025, with significant increases in both revenue and net profit, driven by the sales of core products ARA and DHA [2][3]. Financial Performance - Expected revenue for the first half of 2025 is 307 million yuan, representing a year-on-year growth of 17.59% [2][3]. - Net profit is projected to reach 107 million yuan, showing a year-on-year increase of 57.6%, marking a new quarterly high [2][3]. - Total profit for the period is estimated at 123 million yuan, up 57.82% from the previous year [3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be 100 million yuan, reflecting an 88.51% increase [3]. - The net cash flow from operating activities is reported at 118 million yuan, a decrease of 5.17% compared to the previous year [3]. Business Overview - The company specializes in the research, production, and sales of various products, including ARA, DHA, β-carotene, and N-acetylneuraminic acid [4]. - The company has made progress in developing high-value-added products such as 2'-FL, 3-FL, and EPA, with some products already in the industrialization phase [5]. Industry Events - The Fourth Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will take place from August 20-22 in Ningbo, focusing on AI in bio-manufacturing, green chemicals, new materials, future food, and agriculture [6][7]. - The conference will feature various activities, including a youth forum and high-level discussions on bio-manufacturing [6][15].

Core Insights - The company, Jia Bi You (688089.SH), reported a revenue of 307 million yuan for the first half of 2025, representing a year-on-year growth of 17.60% [1] - The net profit attributable to shareholders reached 108 million yuan, showing a significant increase of 59.01% compared to the previous year [1] - The net profit after deducting non-recurring gains and losses was approximately 99.92 million yuan, reflecting an impressive growth of 88.51% year-on-year [1] - The basic earnings per share (EPS) stood at 0.64 yuan [1] Revenue Growth Drivers - The primary driver for the revenue growth was the increase in sales of ARA and DHA products to domestic customers [1]

格隆汇8月18日丨嘉必优(688089.SH)公布2025年半年度报告，报告期实现营业收入3.07亿元，同比增长 17.60%；归属于上市公司股东的净利润1.08亿元，同比增长59.01%；归属于上市公司股东的扣除非经常 性损益的净利润9992.28万元，同比增长88.51%；基本每股收益0.64元。 ...

一、 募集资金基本情况 （一）募集资金金额及到位时间 经中国证券监督管理委员会《关于同意嘉必优生物技术（武汉）股份有限公 司首次公开发行股票注册的批复》（证监许可〔2019〕2338 号）同意注册，嘉必 优生物技术（武汉）股份有限公司（以下简称"公司"）公开发行人民币普通股（A 股）30,000,000.00 股，每股面值为人民币 1.00 元，发行价格为每股人民币 23.90 元。截至 2019 年 12 月 16 日止，公司实际已发行普通股（A 股）30,000,000.00 股，募集资金总额为人民币 717,000,000.00 元，扣除各项发行费用（不含税）人 民币 68,673,892.62 元，实际募集资金净额为人民币 648,326,107.38 元。上述资金 已于 2019 年 12 月 16 日存入公司募集资金账户中。上述募集资金到位情况业经 立信会计师事务所（特殊普通合伙）验证，并出具了信会师报字[2019]第 ZE10784 号《验资报告》。 证券代码：688089 证券简称：嘉必优 公告编号：2025-059 嘉必优生物技术（武汉）股份有限公司 2025 年半年度募集资金存放与使用情况 ...

2025 年度"提质增效重回报"行动方案的半年度评估报告 为践行以投资者为本的理念，深入落实上海证券交易所关于开展科创板上 市公司"提质增效重回报"专项行动的倡议，嘉必优生物技术（武汉）股份有限 公司（以下简称"公司"）于 2025 年 3 月 28 日发布了《嘉必优生物技术（武汉） 股份有限公司 2025 年度"提质增效重回报"行动方案》（以下简称"行动方案"）。 2025 年上半年，公司按照行动方案，积极开展和落实相关工作，现将 2025 年 上半年主要工作进展及成效情况总结如下： 一、 深耕"一主两翼"业务布局，驱动业务高质量发展 2025 年上半年，公司实现营业收入 3.07 亿元，较上年同期增长 17.60%； 实现归属于上市公司股东的净利润 1.08 亿元，较上年同期增长 59.01%。 嘉必优生物技术（武汉）股份有限公司 婴配领域，国内市场方面，ARA 和藻油 DHA 产品的需求稳步提升，核心 客户销量增长贡献明显。部分大客户藻油 DHA 替换鱼油 DHA 进程加快，公司 全面配合客户替换需求、积极协同下游客户推进产品升级，报告期内藻油 DHA 产品持续快速增长。国际市场方面，2025 年上半年 ...